Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

Published on March 14, 2012 at 2:40 AM · No Comments

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body. The unique ability to inhibit and block the harmful effects of Galectin-3 is one of MCP's many essential health benefits.

This extensive body of research was presented to hundreds of naturopathic oncologists at the Oncology Association of Naturopathic Physicians (OncANP) 2012 Convention & Exposition.

"It's truly rewarding to share cutting-edge research demonstrating Modified Citrus Pectin's ability to promote health and prevent disease," says Dr. Eliaz.

Galectin-3 is a protein produced naturally by our bodies, but elevated levels can lead to chronic inflammation, fibrosis, heart disease, and metastatic cancer. By binding and blocking excess Galectin-3, Modified Citrus Pectin ( prevents this rogue protein from wreaking havoc.

The FDA recently approved a blood test that measures Galectin-3 levels, highlighting a key risk factor for progressive heart failure. The test can also determine Galectin-3 induced risk to the liver, lungs, brain and kidneys, as well as indicate risks of cancer progression and metastasis.

Versatile Health Benefits of MCP
Recent studies demonstrate that Modified Citrus Pectin significantly enhances immune function, and reduces galectin-3 expression and disease severity in kidney injury. Furthermore, MCP is proven through multiple clinical studies to remove lead, mercury, arsenic, and cadmium from the body without reducing essential minerals.

Dr. Eliaz also shared new research showing that MCP, when combined with two advanced poly-botanical formulas, works synergistically to inhibit aggressive breast and prostate cancer cells. This study was presented at the last Experimental Biology meeting and is currently in press for publication.

Read in | English | Español | Deutsch | Italiano | 日本語 | 한국어 | 简体中文 | Русский
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment